NAD+ decline with age: what the research measures

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, first identified more than a century ago. It carries electrons in redox reactions and acts as a substrate for signaling enzymes, which places it at the center of a large and still-moving body of research on cellular aging.

What NAD+ does in the cell

More than 500 enzymatic and redox reactions depend on NAD+. Its roles in the literature group into six areas:

• Energy production
• DNA repair
• Sirtuin activation
• Circadian rhythm regulation
• Cellular signaling
• Cognitive function, studied in neural research

The sirtuin link is the one most cited in aging research. NAD+ activates seven sirtuin proteins, a family of enzymes linked to longevity regulation, as reviewed by Imai and Guarente in Trends in Cell Biology in 2014.

NAD+ pathways also appear in work on cellular repair, including peptide-mediated repair mechanisms. Su and colleagues (2024), writing in Frontiers in Cell and Developmental Biology, examined the mechanisms by which the NAD+ salvage pathway relates to skeletal muscle function. The published data connecting these areas is larger than the general conversation about NAD+ tends to suggest.

What studies report about NAD+ decline with age

A 2022 study in Frontiers in Endocrinology measured whole blood NAD+ in 1,518 people and reported levels about 14% lower in adults over 45 than in younger adults.

Across decades, the literature currently sketches this picture:

• 20s: near-peak levels, with repair and energy metabolism at peak efficiency.
• 30s: a measurable slowdown begins.
• 40s: the roughly 14% lower whole blood levels measured in adults over 45.
• 50s and 60s: broader reviews report levels 40 to 50% below a 20s baseline in some tissue studies.

The larger figures come from tissue studies rather than whole blood, so they are not directly comparable to the 2022 blood measurements.

Where the evidence is contested

The decline is not settled. A 2026 replication study, so far reported through secondary coverage, found no measurable decline in a healthy cohort. That raises a real question about how universal age-related NAD+ decline is in healthy individuals.

This is an active, evolving research area, and the disagreement is worth noting rather than smoothing over.

How the research field is approaching NAD+ metabolism

• Precursor research: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and niacin are the most studied routes to raising blood NAD+ in the clinical literature.
• Lifestyle associations: sleep, fasting windows and exercise intensity have been studied for their association with NAD+ metabolism, as general context.
• Systemic NAD+ research: studies of NAD+ itself, rather than its precursors, are an active clinical and research area.
• Replication: the 2026 replication study has reopened the question of how consistent the decline is across healthy populations.